HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

NNRTI-based HAART regimens have quickly become the preferred choice for initial anti-retroviral therapy, whereas drugs from the newest classes, such as Roche and Pfizer's entry inhibitors and ...

protease inhibitors; entry inhibitors; integrase (strand transfer) inhibitors. Entry inhibitors stop HIV from entering human cells. These include fusion inhibitors, CCR5 inhibitors and attachment ...

C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while C-3 modified betulinic acid derivatives function by blocking virus maturation. [127] Among these bevirimat (Figure 23 ...

and marketed by Roche Pharmaceuticals) offers a new and fourth class of antiretroviral agents called fusion (or entry) inhibitors. Enfuvirtide was approved for use in treatment-experienced ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

entry inhibitor candidate. This Phase 1a study will evaluate the safety, tolerability and pharmacokinetics (PK) of ABI-6250 across single and multiple ascending dose cohorts in healthy participants.

an oral entry inhibitor for hepatitis delta virus or HDV. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-6250 in healthy participants. The trial will assess ...